DSS (DSS) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual Meeting scheduled for December 3, 2025, to elect seven directors, ratify the auditor, and hold an advisory vote on executive compensation.
Proxy materials, including the annual report and proxy statement, are available online and by mail.
Record date for voting is October 6, 2025, with 9,092,518 shares outstanding.
Voting matters and shareholder proposals
Shareholders will vote on electing seven directors, ratifying HTL International, LLC as auditor, and approving executive compensation on an advisory basis.
Board recommends voting in favor of all proposals.
No shareholder proposals were received for the 2025 meeting.
Board of directors and corporate governance
Board consists of seven nominees, including Ambrose Chan Heng Fai (Chairman), with a mix of executive and independent directors.
Four directors qualify as independent under NYSE American standards; committees include Audit, Compensation, and Nominating & Corporate Governance.
Board and committees met regularly in 2024, with high attendance rates.
Code of Ethics and committee charters are available on the company website.
Latest events from DSS
- $10M shelf registration supports a multi-division growth strategy and future public offerings.DSS
Registration Filing16 Dec 2025 - Diversified issuer seeks $10M via shelf registration to fund growth across multiple business lines.DSS
Registration Filing16 Dec 2025 - Proxy covers director elections, auditor ratification, and executive pay, with strong board oversight.DSS
Proxy Filing2 Dec 2025 - Proxy covers director elections, auditor ratification, compensation, and major shareholder control.DSS
Proxy Filing2 Dec 2025 - Revenue up 22% year-over-year, net loss narrows, but going concern risk persists.DSS
Q3 202514 Nov 2025 - Revenue up 27% and net loss narrowed, but going concern risk persists.DSS
Q2 202514 Aug 2025 - Q3 revenue rose 34% year-over-year, but nine-month revenue fell 28% as net losses narrowed.DSS
Q3 202413 Jun 2025 - Revenue and net loss improved sequentially as cost cuts and asset sales offset segment declines.DSS
Q2 202413 Jun 2025 - DSS, Inc. posted a $46.9M net loss in 2024, but completed the Impact BioMedical IPO.DSS
Q4 20249 Jun 2025